UTI

Uro Pipeline: Supplemental application submitted for advanced RCC treatmentOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Spotlight on superbugs sparks concern over catheter useThe standard of care for patients unable to drain their bladder is catheter use, but new alternatives reduce risk of antibiotic-resistant superbugs and costs to the healthcare system.
How to manage recurrent UTIs in postmenopausal women
How to manage recurrent UTIs in postmenopausal womenAlthough there is no clear-cut solution to the problem of recurrent UTIs in postmenopausal women, "various strategies can be employed that have found success," write Wade Bushman, MD, PhD, and Brian V. Le, MD, MA.
Post-cystoscopy urinary tract infection uncommonSymptomatic urinary tract infection is unlikely after office-based cystoscopy, although recent antibiotic exposure or hospitalization raise infection risk, according to a recent study.
Risk calculator predicts breakthrough UTIs in reflux patientsA new study on the use of a reflux calculator, developed at Children’s Hospital of Orange County in Irvine, CA, suggests the web-based risk stratification and probability model helps to predict vesicoureteral reflux patients’ 2-year risk of breakthrough urinary tract infection.
Diet, urine pH may affect urinary tract bacterial growthThe recently published findings may open new avenues for treating urinary tract infections.
UTI incidence high, urine culture-directed care underutilizedGreater use of culture-directed care represents an opportunity to improve management of women with uncomplicated UTIs, researchers say.
Novel agent may protect against major UTI pathogenAn experimental drug that stabilizes a protein protects human bladder cells against a major UTI pathogen, researchers say.
FDA approves antibacterial for complicated UTIThe FDA has approved ceftazidime-avibactam (AVYCAZ) for two indications, including treatment of adults with complicated urinary tract infections who have limited or no alternative treatment options.
FDA approves combination therapy for complicated UTIThe FDA has approved ceftolozane/tazobactam (Zerbaxa) for the treatment of adults with complicated urinary tract infections.